Coleman Glenn 4

What Happened
Glenn Coleman, Chief Financial Officer of Charles River Laboratories (CRL), was granted 6,640 restricted stock units (RSUs) on May 29, 2026. The grant is reported as an acquisition (Form 4 code A) at an implied value of $180.71 per share, totaling $1,199,914. This is a compensation award of unvested equity, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-29; Form 4 filed: 2026-06-02. No late-filing flag provided in the summary information supplied.
• Transaction type: Award / Acquisition (unvested restricted stock units).
• Quantity and value: 6,640 RSUs at $180.71 per share; total value ≈ $1,199,914.
• Shares owned after transaction: Not specified in the provided filing excerpt — see the full Form 4 for current holdings.
• Footnote: F1 — These RSUs are unvested and vest ratably on May 29 of 2027, 2028, 2029 and 2030.
• Tax/withholding or 10b5-1 plan: None reported in the provided details.

Context
RSU grants are a common form of executive compensation and represent a promise of shares that become deliverable only after vesting; they do not indicate an immediate buy or sell in the market. Because these units are unvested and subject to the stated vesting schedule, they’re primarily a retention/compensation tool rather than a direct market sentiment signal. For a complete picture of the CFO’s holdings and any subsequent sales, consult the full Form 4 filing and the company’s proxy/compensation disclosures.